Patient Navigator Program

患者导航程序

• 批准号: 7127667
• 负责人: RICHARD G ROETZHEIM
• 金额: $ 61.78万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-29 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7127667
• 关键词: Patient; Navigator; Program

DESCRIPTION (provided by applicant): The elimination of cancer disparities is a national imperative that requires the creation of accessible and beneficial interventions. The Tampa Bay region of west central Florida epitomizes this challenge, with low levels of education (20% without a high school education), high levels of poverty (12.5% living below the poverty line), a culturally diverse population (18 percent Hispanic and 15 percent African American), and high cancer incidence and mortality rates. Our hypothesis is that a culturally appropriate patient navigator program can be implemented in the Tampa Bay region of Florida that .will decrease delay in diagnosis and delivery of cancer care in an acceptable and cost-effective manner. Our plan is based upon a partnership that includes an NCI designated comprehensive cancer center (H. Lee Moffitt Cancer Center & Research Institute), community hospitals and clinics, the American Cancer Society, and HealthChoice Network. In Phase I we will work closely with our community partners to conduct formative research for the development of an acceptable, appealing, and appropriate Patient Navigator Program/During Phase I we will also obtain baseline data, through chart abstraction, on timeliness and cost of cancer care. Phase II is a group randomized controlled trial to evaluate the Patient Navigator Program. We will focus on patients diagnosed with a breast or colorectal cancer screening abnormality within our participating network. Four centers will receive the Navigator Program, and three will receive the intervention, but delayed. Data will be collected at the time of an abnormal screening finding, and at 1 month, 6 month, 1 year and 2 years to monitor timeliness of care, appropriateness of care, and patient satisfaction and quality of life. Phase III calls for the dissemination of the findings from this research outside the Tampa Bay region. We will Use study outcome data, including results of cost-effectiveness analyses plus input from key stakeholders (participants and providers) to develop a plan for long-term dissemination and sustainability of the program. This study is expected to result in a comprehensive evaluation of a Patient Navigator Program on quality of cancer care, patient satisfaction, quality of life and cost-effectiveness. Such knowledge is essential to improvements in reducing the mortality and suffering from cancer by 2015

描述（由申请人提供）： 消除癌症差异是一项国家要务，需要制定可获得和有益的干预措施。佛罗里达中西部的坦帕湾地区是这一挑战的缩影，教育水平低（20%没有高中教育），贫困水平高（12.5%生活在贫困线以下），文化多样性人口（18%西班牙裔和15%非裔美国人），癌症发病率和死亡率高。我们的假设是，一个文化上合适的病人导航程序可以在佛罗里达的坦帕湾地区实施，这将减少延误诊断和提供癌症护理在一个可接受的和具有成本效益的方式。我们的计划是基于一个伙伴关系，其中包括NCI指定的综合癌症中心（H。Lee Moffitt癌症中心和研究所）、社区医院和诊所、美国癌症协会和健康选择网络。在第一阶段，我们将与我们的社区合作伙伴密切合作，进行形成性研究，以开发可接受的，有吸引力的和适当的患者导航程序/在第一阶段，我们还将通过图表摘要获得有关癌症护理的及时性和成本的基线数据。II期是一项评估Patient Navigator程序的分组随机对照试验。我们将重点关注我们参与网络中诊断为乳腺癌或结直肠癌筛查异常的患者。四个中心将接受导航程序，三个将接受干预，但推迟。将在出现异常筛选结果时以及1个月、6个月、1年和2年时收集数据，以监测护理的及时性、护理的适当性以及患者满意度和生活质量。第三阶段要求在坦帕湾地区以外传播这项研究的结果。我们将使用研究结果数据，包括成本效益分析的结果以及关键利益相关者（参与者和提供者）的投入，以制定计划的长期传播和可持续性。这项研究预计将导致对癌症护理质量，患者满意度，生活质量和成本效益的患者导航程序的全面评估。这些知识对于到2015年减少癌症死亡率和痛苦至关重要